Scancell Holdings (GB:SCLP) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Scancell Holdings has reported a successful year with its lead cancer vaccine SCIB1 showing promising results in a Phase 2 trial for melanoma, exceeding the 70% objective response rate target, while also progressing with its Modi-1 vaccine and securing strategic partnerships. The company’s financial position remains solid with an operating loss of £18.3 million, a cash balance of £14.8 million, and a cash runway extending into the third quarter of 2025. Key organizational appointments have been made, positioning Scancell for pivotal studies and further development in the coming years.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.